MCB
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kindle, K. B.
Right arrow Articles by Heery, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kindle, K. B.
Right arrow Articles by Heery, D. M.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, February 2005, p. 988-1002, Vol. 25, No. 3
0270-7306/05/$08.00+0     doi:10.1128/MCB.25.3.988-1002.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

MOZ-TIF2 Inhibits Transcription by Nuclear Receptors and p53 by Impairment of CBP Function

Karin B. Kindle,1,{dagger} Philip J. F. Troke,1,{dagger},{ddagger} Hilary M. Collins,1 Sachiko Matsuda,1 Daniela Bossi,2 Cristian Bellodi,3 Eric Kalkhoven,4 Paolo Salomoni,3 Pier Giuseppe Pelicci,2 Saverio Minucci,2 and David M. Heery1*

Department of Biochemistry,1 Medical Research Council Toxicology Unit, University of Leicester, Leicester, United Kingdom,3 Department of Experimental Oncology, European Institute of Oncology, Milan, Italy,2 Department of Metabolic and Endocrine Diseases, UMC Utrecht, Utrecht, The Netherlands4

Received 20 July 2004/ Returned for modification 24 September 2004/ Accepted 8 November 2004

Chromosomal rearrangements associated with acute myeloid leukemia (AML) include fusions of the genes encoding the acetyltransferase MOZ or MORF with genes encoding the nuclear receptor coactivator TIF2, p300, or CBP. Here we show that MOZ-TIF2 acts as a dominant inhibitor of the transcriptional activities of CBP-dependent activators such as nuclear receptors and p53. The dominant negative property of MOZ-TIF2 requires the CBP-binding domain (activation domain 1 [AD1]), and coimmunoprecipitation and fluorescent resonance energy transfer experiments show that MOZ-TIF2 interacts with CBP directly in vivo. The CBP-binding domain is also required for the ability of MOZ-TIF2 to extend the proliferative potential of murine bone marrow lineage-negative cells in vitro. We show that MOZ-TIF2 displays an aberrant nuclear distribution and that cells expressing this protein have reduced levels of cellular CBP, leading to depletion of CBP from PML bodies. In summary, our results indicate that disruption of the normal function of CBP and CBP-dependent activators is an important feature of MOZ-TIF2 action in AML.

* Corresponding author. Present address: School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom. Phone: (44) 115-8466248. Fax: (44) 115-8466249. E-mail: david.heery{at}nottingham.ac.uk.

{dagger} K.B.K. and P.J.F.T. contributed equally to this work.

{ddagger} Present address: Department of Pathology, Harvard Medical School, Boston, Mass.

Molecular and Cellular Biology, February 2005, p. 988-1002, Vol. 25, No. 3
0022-538X/05/$08.00+0     doi:10.1128/MCB.25.3.988-1002.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2005 by the American Society for Microbiology. All rights reserved.